The turning point came on December 23, 1954, at what was then the Peter Bent Brigham Hospital in Boston. Richard Herrick was dying of end-stage renal disease when his identical twin brother Ronald offered one of his kidneys. Their genetic identity provided a unique opportunity to sidestep the immunological barrier that had defeated every previous attempt at clinical transplantation. Murray and his team successfully replaced Richard’s failing organ, converting transplantation from an experimental concept into a viable surgical therapy. Richard survived for eight years after the procedure, married his recovery room nurse, and together they had two children. What made the achievement remarkable, the authors emphasize, was not only its technical success but the broad potential it revealed: surgery could now be judged by the life an operation made possible afterward.

Yet the Herrick case also exposed a fundamental limitation. Even the most technically successful operation could fail if the biology of the underlying disease was not understood or if post-operative treatment did not meet the recipient’s specific immunological needs. During the 1950s, Peter Medawar established that graft rejection was an active immunological response to genetically different tissue, providing the biological explanation for why transplantation beyond identical twins remained so difficult. His work shifted the central problem of transplantation from replacing an organ to controlling the recipient’s response to it, a reframing that would define the next several decades of research and clinical practice.

Through the early 1960s and 1970s, Murray and other transplant pioneers, including Thomas Starzl and Roy Calne, translated this emerging immunological understanding into increasingly effective clinical regimens. Immunosuppression based on azathioprine and corticosteroids, followed by the introduction of Cyclosporin A, demonstrated that the immune response could be suppressed sufficiently to allow genetically non-identical grafts to survive, substantially improving transplant outcomes. Murray later reflected that the full story of successful organ transplantation in humans weaves together three separate pathways: the study of renal disease, skin grafting in twins, and surgical determination. The lesson extended far beyond transplantation, the article argues. Technical excellence alone could not determine the outcome of an operation; success increasingly depended on understanding the biological environment in which an intervention was performed and developing effective strategies to control it.

The ability to transplant organs successfully also raised questions surgery had never confronted before: who could be asked to donate, what risks were acceptable, and who should receive a scarce organ? The ethical tension was present from the very first transplant. Ronald Herrick underwent major surgery while healthy, solely to benefit his brother. Murray later described this as an unprecedented ethical dilemma, noting that the only remaining problem was the ethical decision concerning the removal of a healthy organ from a normal person for the benefit of someone else. As transplantation expanded beyond identical twins and living relatives, living donation demanded careful consideration of donor autonomy and acceptable risk, while deceased donation raised even more fundamental questions about when death itself could be declared.

That last question received a formal answer in 1968, when an ad hoc committee at Harvard Medical School proposed criteria for irreversible coma as a new standard, establishing the concept of death by neurologic criteria. The framework addressed the ethical dilemma created by transplantation and modern life-sustaining technology, allowing organs to be recovered while they remained viable only after a clear determination that the donor had died. Scarcity added a further layer of responsibility: even technically successful transplantation could not be offered to everyone who might benefit. Allocation became an integral part of transplant medicine, requiring decisions not only about whether transplantation could succeed but about who should have access to an organ, under what conditions, and according to which principles.

Institutional structures emerged to formalize those decisions. The establishment of the United Network for Organ Sharing in 1986 marked an important step forward. As the organization responsible for operating the national Organ Procurement and Transplantation Network, UNOS helped coordinate organ allocation across the United States and introduced a common framework for evaluating and improving transplant practice. Transplantation, in other words, expanded the boundaries of surgical responsibility beyond the patient and the operation itself, making the ethical framework in which surgery was performed part of what defined its success.

Success also proved impossible to achieve alone. From the earliest transplant programs, surgeons worked alongside nephrologists, anesthesiologists, pathologists, nurses, and other specialists whose contributions were essential to patient selection, perioperative management, immunosuppression, and the recognition and treatment of complications. The collaboration between Murray and nephrologist John Merrill exemplified this emerging model: Murray’s surgical skill was complemented by Merrill’s knowledge of renal failure and dialysis, allowing transplantation to become part of a broader therapeutic strategy rather than an isolated operation. Murray himself later observed that if gold medals and prizes were awarded to institutions instead of individuals, the Peter Bent Brigham Hospital of thirty years earlier would have qualified. As transplantation expanded to other organs, this collaborative model became an integral part of surgical care across disciplines.

As the field matured, it became clear that discharging a patient from the hospital marked only the beginning of treatment. Graft function required careful long-term monitoring, with rejection and complications occurring months or even years later, and immunosuppression, still broad and unspecific today, carried substantial complications of its own. Murray was among the early transplant surgeons to put long-term assessment into practice, systematically documenting graft function, patient survival, and causes of graft failure in his recipients. In 1963 he brought together early transplant investigators from centers around the world, and by the following year data on 342 renal transplants performed worldwide had been assembled. That early effort demonstrated the value of systematically collecting outcomes and paved the way for much larger longitudinal assessment. The U.S. National Organ Transplant Act of 1984 provided the legal framework for national outcome monitoring, followed by the establishment of the Scientific Registry of Transplant Recipients in 1987 to track outcomes across the transplant continuum, from waiting-list candidates and donors to recipients and long-term survival.

Over years of follow-up, a further insight emerged: a functioning graft did not necessarily mean a patient had returned to a normal life. Patients could survive for decades with a working organ while facing lifelong treatment-related complications, persistent symptoms, or limitations in their physical and overall well-being. Patient-reported outcome measures arose to close this gap, capturing dimensions beyond standard clinical endpoints, including physical activity, treatment burden, and quality of life as reported by patients themselves. This growing emphasis on the patient’s perspective strengthened patient-centered care and shared decision-making, with treatment goals increasingly incorporating what patients valued, their priorities, preferences, and willingness to accept the burdens of lifelong treatment. The evolution, the authors note, came full circle in Murray’s own career: his early work with skin grafts sparked his pioneering success in organ transplantation, which eventually brought him back to his original passion for plastic surgery. The article, written by Pia F. Koch and Stefan G. Tullius of Brigham and Women’s Hospital, Harvard Medical School, and Charité Universitätsmedizin Berlin, concludes that modern surgical success is no longer defined by what happens during an operation, but by what that operation ultimately makes possible, a paradigm shift that prioritizes functional rehabilitation, long-term patient health, and quality of life within a multidisciplinary approach.

Subject of Research: The evolution of surgical success through the history of organ transplantation and Joseph E. Murray's contributions

Article Title: Joseph E Murray, MD: redefining surgical success through the evolution of transplantation

Article References: Koch, P. F., & Tullius, S. G. (2026). Joseph E Murray, MD: redefining surgical success through the evolution of transplantation. Frontiers in Transplantation, 5, Article 1995998. https://doi.org/10.3389/frtra.2026.1995998

Image Credits: AI Generated

DOI: 10.3389/frtra.2026.1995998

Keywords: Joseph E. Murray, organ transplantation, kidney transplant, surgical success, immunosuppression, graft rejection, organ allocation, UNOS, patient-reported outcomes, transplant history, quality of life, Nobel Prize